The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Tirzepatide: A Review in Type 2 Diabetes
Open accessAbstract
Tirzepatide (Mounjaro®), a first-in-class dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is approved for use as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM) in the USA, EU, Japan and other countries. It comes as single-dose prefilled pens and single-dose vials. In phase III SURPASS trials, once-weekly subcutaneous tirzepatide, as monotherapy or add-on-therapy to oral glucose-lowering medications and insulin, was superior to the GLP-1 receptor agonists (RAs) dulaglutide 0.75 mg and semaglutide 1 mg as well as basal and prandial insulin for glycaemic control and weight loss in adults with inadequately controlled T2DM. Tirzepatide was generally well tolerated, with a safety profile consistent with that of GLP-1 RAs. Tirzepatide was associated with a low risk of clinically significant or severe hypoglycaemia and no increased risk of major adverse cardiovascular events. Adverse events were mostly mild to moderate in severity, with the most common being gastrointestinal events including nausea, diarrhoea, decreased appetite and vomiting. In conclusion, tirzepatide is a valuable addition to the treatment options for T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Common side effects include gastrointestinal reactions, such as nausea and vomiting, which are typically more common during the initial stages of treatment.141,142”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [142]
In the citing paper
“Across a pool of nine phase 2 and phase 3 clinical trials in people with T2D, acute pancreatitis was reported in 0.24% of participants with tirzepatide vs 0.13% with the comparators and acute gallbladder adverse events were reported in 1.1% of participants with tirzepatide vs 0.6% with the comparators [55].”
In the citing paper
“Across a pool of nine phase 2 and phase 3 clinical trials in people with T2D, acute pancreatitis was reported in 0.24% of participants with tirzepatide vs 0.13% with the comparators and acute gallbladder adverse events were reported in 1.1% of participants with tirzepatide vs 0.6% with the comparators [55].”
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 10×
“US and EU treatment guidelines recommend a holistic person-centred approach to T2DM management, with the goals being to prevent complications and optimize quality of life [2, 41, 42].”
InfluentialTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 5×
“Tirzepatide administration also reduced food intake and body weight in a diet-induced obese mouse model [12].”
Influential9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 4×
“The trial supported further evaluation of tirzepatide 5, 10 and 15 mg and found all three doses of tirzepatide significantly reduced glycated haemoglobin A 1c (HbA 1c ) [ p ≤ 0.0152] and tirzepatide 10 and 15 mg significantly reduced body weight ( p 0.0001) compared with dulaglutide 1.5 mg [26].”
InfluentialDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Research works printed but not linked: 1
- Goyal RJI. Type 2 diabetes. [updated 2023 June 23] In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2023. https://www.ncbi.nlm.nih.gov/pubmed/30020625. Accessed 19 Dec 2023.
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“141,142 The Phase III clinical trials of tirzepatide were conducted in 77 research centers across seven countries, including the United States, Brazil, and Japan.”
BackgroundAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Progress in peptide and protein therapeutics: Challenges and strategies
Liu, M., Svirskis, D. M., Proft, T., Loh, J. M. S., Yin, N., Li, H., Li, D., Zhou, Y., Chen, S., Song, L., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.026 · Cited by 129
Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy
Li, Q., Chao, W., & Qiu, L. (2025) · Amino Acids · doi:10.1007/s00726-025-03454-5 · Cited by 68
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas, F., Şener, Y. Z., Golforoush, P. A., Kheirkhah, A., Rodríguez‐Sánchez, E., Novák, J., Apellániz-Ruiz, M., Akyea, R. K., Bianconi, V., Ceasovschih, A., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117579 · Cited by 64
Metadata
- Authors
- France, N. L., & Syed, Y. Y.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- France, Nicole L.
- ORCID
- Syed, Yahiya Y.
- Venue
- Drugs
- Published
- 2024-02
- Volume
- 84
- Issue
- 2
- Pages
- 227-238
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W4392773706
- Cited by
- 51
- References
- 40
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 9
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by-nc
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by-nc)
- Figshare
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- tirzepatide, type 2 diabetes, GIP/GLP-1 receptor agonist, glycemic control, weight loss, dulaglutide, semaglutide, insulin, hypoglycemia, gastrointestinal adverse effects, drug safety, SURPASS trials, cardiovascular safety, pharmacokinetics, pharmacodynamics, drug interactions, dosage
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Tirzepatide, Adult, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucose, Humans, Hypoglycemic Agents, Insulin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide: A Review in Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s40265-023-01992-4
- The paper
- France, N. L., & Syed, Y. Y. (2024). Tirzepatide: A Review in Type 2 Diabetes. Drugs. https://doi.org/10.1007/s40265-023-01992-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.